AR058162A1 - Derivados de indol beta-agonistas, procedimiento para prepararlos, composiciones farmaceuticas que los contienen y usos como agentes antidiabeticos y antilipidemicos - Google Patents

Derivados de indol beta-agonistas, procedimiento para prepararlos, composiciones farmaceuticas que los contienen y usos como agentes antidiabeticos y antilipidemicos

Info

Publication number
AR058162A1
AR058162A1 ARP060104696A ARP060104696A AR058162A1 AR 058162 A1 AR058162 A1 AR 058162A1 AR P060104696 A ARP060104696 A AR P060104696A AR P060104696 A ARP060104696 A AR P060104696A AR 058162 A1 AR058162 A1 AR 058162A1
Authority
AR
Argentina
Prior art keywords
group
alkyl
carbonyl
substituted
alkyloxy
Prior art date
Application number
ARP060104696A
Other languages
English (en)
Inventor
Rainer Walter
Bradford S Hamilton
Thomas Trieselmann
Matthew R Netherton
Marco Santagostino
Ingo Konetzki
Original Assignee
Boehringer Ingelheim Int
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Ingelheim Int filed Critical Boehringer Ingelheim Int
Publication of AR058162A1 publication Critical patent/AR058162A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/08—Indoles; Hydrogenated indoles with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to carbon atoms of the hetero ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/18—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
    • C07D209/42—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Endocrinology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Psychology (AREA)
  • Reproductive Health (AREA)
  • Psychiatry (AREA)
  • Cardiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Child & Adolescent Psychology (AREA)
  • Emergency Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Vascular Medicine (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pain & Pain Management (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Indole Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Reivindicacion 1: Compuestos de formula general (1) en la cual R1 significa un grupo fenilo que puede estar monosustituido o disustituido con átomos de fluor, de cloro o de bromo, o con grupos metilo, metoxi, trifluorometoxi o difluorometoxi, siendo los sustituyentes iguales o diferentes, o bien un grupo heteroarilo seleccionado del grupo consistente en piridinilo y tienilo, y R2 significa un átomo de hidrogeno, de fluor, de cloro, de bromo o de yodo, un grupo nitro, ciano, trifluorometoxi, difluorometoxi, carboxi-, 2,2,2-trifluoroacetilo, (alquil C1-3)-sulfanilo, (alquil C1-3)-sulfinilo, (alquil C1-3)-sulfonilo, tetrazolilo, 5-oxo-4,5-didhidro-[1,3,4]oxadiazol-2-ilo o 5-oxo-2,5-dihidro-[1,2,4]oxadiazol-3-ilo, un grupo amino que puede estar sustituido con un grupo carboxicarbonilo, amino-carbonilo, (alquil C1-6)-aminocarbonilo, fenilaminocarbonilo, (alquil C1-6)-carbonilo, benciloxi-(alquilC1-3)-carbonilo, ciano-(alquil C1-3)carbonilo, (cicloalquil C3-7)-carbonilo o (alquil C1-3)- sulfonilo, pudiendo los grupos (alquil C1-6)-carbonilo antes mencionados ser de cadena lineal o ramificados, y pudiendo estar sustituidos en la parte alquílica con un grupo amino, un grupo alquilo C1-3 que, de manera independiente entre sí, puede estar sustituido con uno o dos grupos trifluorometilo, hidroxi, carboxi o (alquiloxi C1-6)-carbonilo, un grupo alquenilo C2-3, que puede estar sustituido con un grupo carboxi, un grupo alquiloxi C1-3, que puede estar sustituido con un grupo carboxi o (alquiloxi C1-3)-carbonilo, un grupo (alquil C1-3)-carbonilo, que puede estar sustituido con un grupo (alquil C1-3)-sulfonilo, grupo (alquiloxi C1-6)-carbonilo, que puede estar sustituido en la parte alquílica con un grupo di-(alquil C1-3)-amino- carbonilo, (alquil C1-6)-carboniloxi, (alquiloxi C1-6)-carboniloxi o piridinilo, o bien con un grupo 2-oxo-[1,3]dioxolilo eventualmente sustituido con un grupo alquilo C1-3, grupo (alquiloxi C2-6)-carbonilo, que puede estar sustituido en la parte alquílica, a partir de la posicion 2, con un grupo di-(alquil C1-4)-amino, N-(alquil C1-3)-N-bencil-amino o (alquiloxi C1-3)-(alquiloxi C1-3, o con un grupo cicloalquilenimino de 3 a 7 eslabones, pudiendo, en el grupo cicloalquilenimino de 5 a 7 eslabones antes mencionado, estar reemplazados uno o dos grupos metileno, de manera independiente enrte sí, por un átomo de oxígeno o de azufre, y/o un grupo carbonilo, sulfonilo o -N(alquilo C1-3), un grupo aminocarbonilo, que puede estar sustituido en el átomo de nitrogeno, de manera independiente entre sí, con uno o dos grupos seleccionados del grupo que consiste en ciano, hidroxi, alquilo C1-6, cicloalquilo C3-7, alcoxi C1-3, amino, di-(alquil C1-3)-amino, (4-metil-fenil)- sulfonilo, pudiendo ser los gurpos alquilo antes mencionados de cadena lineal o ramificados, y pudiendo estar sustituidos con uno hasta tres átomos de fluor, o con un grupo carboxi, (alcoxi C1-3)-carbonilo, cicloalquilo C3-7 o (alquil C1-3)- sulfonilo, un grupo carbonilo, que está sustituido con un grupo cicloalquilennimino de 3 a 7 eslabones, pudiendom en el grupo cicloalquilennimino de 5 a 7 eslabones antes mencionado, estar reemplazado un grupo metileno por un átomo de oxígeno o de azufre, o un grupo carbonilo o sulfonilo, o bien un grupo de formula (2) en la cual R significa un átomo de hidrogeno o un grupo hidroxi, pudiendo ser los grupos alquilo contenidos en los grupos antes mencionados, en cada caso, de cadena lineal o ramificados, así como sus profármacos, tautomeros, racematos, enantiomeros, diastereoisomeros, solvatos, hidratos, sus mezclas y sus sales.
ARP060104696A 2005-10-28 2006-10-27 Derivados de indol beta-agonistas, procedimiento para prepararlos, composiciones farmaceuticas que los contienen y usos como agentes antidiabeticos y antilipidemicos AR058162A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE102005052127A DE102005052127A1 (de) 2005-10-28 2005-10-28 Neue indol-haltige Beta-Agonisten, Verfahren zu deren Herstellung und deren Verwendung als Arzneimittel

Publications (1)

Publication Number Publication Date
AR058162A1 true AR058162A1 (es) 2008-01-23

Family

ID=37820611

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP060104696A AR058162A1 (es) 2005-10-28 2006-10-27 Derivados de indol beta-agonistas, procedimiento para prepararlos, composiciones farmaceuticas que los contienen y usos como agentes antidiabeticos y antilipidemicos

Country Status (15)

Country Link
US (1) US7754756B2 (es)
EP (1) EP1943220A2 (es)
JP (1) JP2009514817A (es)
KR (1) KR20080065674A (es)
CN (1) CN101296903A (es)
AR (1) AR058162A1 (es)
AU (1) AU2006307907A1 (es)
BR (1) BRPI0617851A2 (es)
CA (1) CA2627486A1 (es)
DE (1) DE102005052127A1 (es)
PE (1) PE20070694A1 (es)
TW (1) TW200800187A (es)
UY (1) UY29883A1 (es)
WO (1) WO2007048841A2 (es)
ZA (1) ZA200803116B (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102004021779A1 (de) * 2004-04-30 2005-11-24 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue Beta-Agonisten, Verfahren zu deren Herstellung und deren Verwendung als Arzneimittel
DE102005052101A1 (de) * 2005-10-28 2007-05-03 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue Beta-Agonisten, Verfahren zu deren Herstellung und deren Verwendung als Arzneimittel
DE102005052102A1 (de) * 2005-10-28 2007-05-03 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue Beta-Agonisten, Verfahren zu deren Herstellung und deren Verwendung als Arzneimittel
US8338416B2 (en) * 2006-03-16 2012-12-25 Pharmacylics, Inc. Indole derivatives as inhibitors of histone deacetylase
WO2008132162A1 (en) * 2007-04-26 2008-11-06 Boehringer Ingelheim International Gmbh 3- (sulphonylamino) -phenyl-2 -hydroxy-ethylamino derivatives useful as beta-agonists, processes for preparing them and their use as medicaments
CN102764438A (zh) * 2012-01-30 2012-11-07 林曙光 β3肾上腺素受体激动剂的新用途
CN107434819B (zh) * 2017-02-15 2020-03-17 河北医科大学第二医院 吲哚-tempo缀合物及其在保护远隔器官对抗缺血再灌注损伤中的用途

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2943090A (en) 1957-09-23 1960-06-28 American Cyanamid Co Substituted piperazines and method of preparing the same
US3092636A (en) 1959-10-21 1963-06-04 Upjohn Co Alpha-[2-(1-alkyleneimino) ethylamino]-alkanophenones and the corresponding alcohols
GB1200886A (en) 1966-09-23 1970-08-05 Allen & Hanburys Ltd Phenylaminoethanol derivatives
DE2115926C3 (de) 1971-04-01 1978-05-03 C.H. Boehringer Sohn, 6507 Ingelheim 1 -(4-Hydroxy-3-dimethylaminosuIfamidophenyI)-2-aminoäthanderivate, Verfahren zu ihrer Herstellung und diese enthaltende Mittel
DE2609645A1 (de) 1976-03-09 1977-09-15 Boehringer Sohn Ingelheim Aminoalkylheterocyclen
DE2833140A1 (de) 1978-07-28 1980-02-07 Boehringer Sohn Ingelheim Neue n-substituierte heterocyclen
JPS6183147A (ja) 1984-09-28 1986-04-26 Nippon Chemiphar Co Ltd 新規なアミノアルコール誘導体およびその製造法並びにそれを有効成分とするグルタミン酸遮断剤
US5776983A (en) 1993-12-21 1998-07-07 Bristol-Myers Squibb Company Catecholamine surrogates useful as β3 agonists
IL113410A (en) 1994-04-26 1999-11-30 Merck & Co Inc Substituted sulfonamides having an asymmetric center and pharmaceutical compositions containing them
GB9525177D0 (en) 1995-12-08 1996-02-07 Glaxo Group Ltd Chemical compounds
GB9805520D0 (en) 1998-03-17 1998-05-13 Zeneca Ltd Chemical compounds
GB2356197A (en) 1999-10-12 2001-05-16 Merck & Co Inc Amide derivatives as beta 3 agonists
AUPQ585000A0 (en) 2000-02-28 2000-03-16 Fujisawa Pharmaceutical Co., Ltd. Aminoalcohol derivatives
AU2001252575A1 (en) 2000-04-28 2001-11-12 Asahi Kasei Kabushiki Kaisha Novel tricyclic compounds
DK1277736T3 (da) 2000-04-28 2007-10-01 Asahi Kasei Pharma Corp Hidtil ukendte bicykliske forbindelser
ATE340794T1 (de) * 2001-08-14 2006-10-15 Lilly Co Eli Indol derivate als beta-3-adrenerge agonisten zur behandlung von typ 2 diabetes
EP1935882B1 (en) 2001-10-25 2011-02-09 Asahi Kasei Pharma Corporation Bicyclic compounds
EP1514869A1 (en) * 2002-06-12 2005-03-16 Sumitomo Pharmaceuticals Company, Limited Indole, indazole, and benzazole derivative
US20040127733A1 (en) 2002-10-31 2004-07-01 Boehringer Ingelheim Pharma Gmbh & Co. Kg New beta-agonists, processes for preparing them and their use as pharmaceutical compositions
DE10251170A1 (de) 2002-10-31 2004-05-13 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue Beta-Agonisten, Verfahren zu deren Herstellung und deren Verwendung als Arzneimittel
JP2004323519A (ja) * 2003-04-10 2004-11-18 Dainippon Pharmaceut Co Ltd スルホン酸アニリド誘導体及びそれを含有する医薬組成物
DE102004021779A1 (de) 2004-04-30 2005-11-24 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue Beta-Agonisten, Verfahren zu deren Herstellung und deren Verwendung als Arzneimittel
DE102005052101A1 (de) 2005-10-28 2007-05-03 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue Beta-Agonisten, Verfahren zu deren Herstellung und deren Verwendung als Arzneimittel
DE102005052102A1 (de) 2005-10-28 2007-05-03 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue Beta-Agonisten, Verfahren zu deren Herstellung und deren Verwendung als Arzneimittel
DE102005052103A1 (de) 2005-10-28 2007-05-03 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue Beta-Agonisten, Verfahren zu deren Herstellung und deren Verwendung als Arzneimittel

Also Published As

Publication number Publication date
AU2006307907A1 (en) 2007-05-03
UY29883A1 (es) 2007-05-31
CA2627486A1 (en) 2007-05-03
US7754756B2 (en) 2010-07-13
DE102005052127A1 (de) 2007-05-03
WO2007048841A3 (de) 2007-06-21
CN101296903A (zh) 2008-10-29
US20070105906A1 (en) 2007-05-10
PE20070694A1 (es) 2007-08-21
JP2009514817A (ja) 2009-04-09
BRPI0617851A2 (pt) 2011-08-09
TW200800187A (en) 2008-01-01
WO2007048841A2 (de) 2007-05-03
EP1943220A2 (de) 2008-07-16
ZA200803116B (en) 2009-09-30
KR20080065674A (ko) 2008-07-14

Similar Documents

Publication Publication Date Title
AR058162A1 (es) Derivados de indol beta-agonistas, procedimiento para prepararlos, composiciones farmaceuticas que los contienen y usos como agentes antidiabeticos y antilipidemicos
AR066669A1 (es) Derivados de imidazolona como inhibidores de bencimidazolona quimasa. composiciones farmaceuticas.
AR076435A1 (es) Compuestos de indazoles sustituidos, composiciones farmaceuticas que los contienen y procesos de obtencion de los mismos
AR083936A1 (es) Derivados pirazolicos de bisamida aromaticas, composiciones insecticidas que los contienen y metodos de utilizacion de los mismos para combatir y controlar plagas
CO6160235A2 (es) Isoxazolinas insecticidas
AR054688A1 (es) Alquil-piridinas como inhibidores 11-beta de la diabetes
ECSP088294A (es) Formulación en aerosol para la inhalación de beta-agonistas
CO6280485A2 (es) Inhibidores de 11-beta hidroxiesteroide deshidrogenasa tipo i de triazolopiridina
PE20141583A1 (es) Nuevos derivados de piridina
AR041250A1 (es) Derivados de sulfonamida como inhibidores de enzimas convertidoras de tnf-alfa
AR057467A1 (es) Sales de 4- metil-n-(3-(4-metilimidazol-1-il)-5- trifluorometil- fenil)-3- (4- metil- imidazol-1-il)-5- trifluorometil - fenil)-3-(4- piridin -3- il pirimidin-2- lamino ) - benzamida. metodo de preparacion y composiciones farmaceuticas
AR055613A1 (es) Formas cristalinas delta y epsilon de mesilato de imatinib
AR059778A1 (es) Compuestos de pirrolotriazina inhibidores de quinasas p38,composiciones farmaceuticas que los contienen y usos en gran variedad de procesos inflamatorios.
AR056047A1 (es) Derivados de bencil - benceno sustituidos con glucopiranosilo, medicamentos que contienen dichos compuestos, su uso y procedimiento para su preparacion.
AR059494A1 (es) Derivados biciclicos de bisamida con actividad pesticida
AR083810A2 (es) Derivados de pirazincarboxanilida sustituidos o sus sales
AR062677A1 (es) Derivados de biaril-sulfonamida, procesos de produccion y composiciones farmaceuticas que los comprenden
AR085318A1 (es) Derivados de triazol que tienen actividad insecticida
ES2531256T3 (es) Amidas fungicidas
PE20090288A1 (es) Derivados de quinoxalina como inhibidores de la pi3 quinasa
ECSP066695A (es) Derivados de n-(1,5-difenil-1h-pirazol-3-il) sulfonamida con afinidad por los receptores cb1
ATE455103T1 (de) Als antikoagulationsmittel geeignete phenylglycinamid- und pyridylglycinamidderivate
PE20090641A1 (es) Amidas heterociclicas
AR068061A1 (es) Derivados de bisamida biciclicos utiles como pesticidas
AR062425A1 (es) Formulacion de aerosol para la inhalacion de agonistas beta

Legal Events

Date Code Title Description
FB Suspension of granting procedure